Literature DB >> 33393026

Impact of Surgical Modalities on Long-term Survival Outcomes of Patients with Duodenal Gastrointestinal Stromal Tumor.

You-Zhu Wei1, Zhi-Bin Cai1, Chen-Long Zhu1, Yan-Ming Zhou2,3, Xiao-Feng Zhang4.   

Abstract

BACKGROUND: The optimal surgical modality for duodenal gastrointestinal stromal tumor (GIST) remains undefined. The purpose of this study was to evaluate long-term survival outcomes of patients who underwent radical resection (RR) or limited resection (LR) of duodenal GIST.
METHODS: A total of 325 patients identified from the Surveillance, Epidemiology and End Results (SEER) database who underwent surgery for duodenal GIST between 1986 and 2016 were classified into a LR group and a RR group based on the type of surgery received. Propensity score matching (PSM) was performed to minimize the selection bias in comparisons. Disease-specific survival (DSS) and overall survival (OS) were observed, and factors affecting the survival outcome were analyzed.
RESULTS: In the entire cohort, 105 patients (32.3%) underwent RR and 220 (67.7%) received LR. Both the 5-year OS and DSS in RR group were significantly better than those in LR group (71.0% vs. 54.1%, P = 0.014; 66.6% vs. 49.1%, P = 0.025). PSM resulted in 95 pairs of patients, with long-term outcomes being comparable between the two groups. After adjusting covariates in the propensity matched cohort, the type of surgery still showed no significant impact on OS (hazard ratio [HR] 1.160; 95% confidence interval [CI] 0.662-2.033) and DSS (HR 1.208; 95% CI 0.686-2.128).
CONCLUSIONS: Surgical modalities do not seem to have a significant impact on long-term survival outcomes of patients with duodenal GIST and should mainly depend on the tumor size and location.

Entities:  

Year:  2021        PMID: 33393026     DOI: 10.1245/s10434-020-09497-0

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  9 in total

Review 1.  A systematic review and meta-analysis comparing pancreaticoduodenectomy versus limited resection for duodenal gastrointestinal stromal tumors.

Authors:  Aik-Yong Chok; Ye-Xin Koh; Mandy Y L Ow; John C Allen; Brian K P Goh
Journal:  Ann Surg Oncol       Date:  2014-05-23       Impact factor: 5.344

2.  Presentation and management of gastrointestinal stromal tumors of the duodenum: a multi-institutional analysis.

Authors:  Fabian M Johnston; Peter J Kneuertz; John L Cameron; Dominic Sanford; Sarah Fisher; Ryan Turley; Ryan Groeschl; Omar Hyder; David A Kooby; Dan Blazer; Michael A Choti; Christopher L Wolfgang; T Clark Gamblin; William G Hawkins; Shishir K Maithel; Timothy M Pawlik
Journal:  Ann Surg Oncol       Date:  2012-08-10       Impact factor: 5.344

Review 3.  Gastrointestinal stromal tumors (GIST) from risk stratification systems to the new TNM proposal: more questions than answers? A review emphasizing the need for a standardized GIST reporting.

Authors:  Abbas Agaimy
Journal:  Int J Clin Exp Pathol       Date:  2010-05-05

4.  Surgical Strategy and Outcomes in Duodenal Gastrointestinal Stromal Tumor.

Authors:  Ser Yee Lee; Brian K P Goh; Eran Sadot; Rahul Rajeev; Vinod P Balachandran; Mithat Gönen; T Peter Kingham; Peter J Allen; Michael I D'Angelica; William R Jarnagin; Daniel Coit; Wai Keong Wong; Hock Soo Ong; Alexander Y F Chung; Ronald P DeMatteo
Journal:  Ann Surg Oncol       Date:  2016-09-13       Impact factor: 5.344

5.  Clinical, pathological and surgical characteristics of duodenal gastrointestinal stromal tumor and their influence on survival: a multi-center study.

Authors:  C Colombo; U Ronellenfitsch; Z Yuxin; P Rutkowski; R Miceli; E Bylina; P Hohenberger; C P Raut; A Gronchi
Journal:  Ann Surg Oncol       Date:  2012-07-28       Impact factor: 5.344

6.  Neoadjuvant imatinib in locally advanced gastrointestinal stromal tumors (GIST): the EORTC STBSG experience.

Authors:  Piotr Rutkowski; Alessandro Gronchi; Peter Hohenberger; Sylvie Bonvalot; Patrick Schöffski; Sebastian Bauer; Elena Fumagalli; Pawel Nyckowski; Buu-Phuc Nguyen; Jan Martijn Kerst; Marco Fiore; Elzbieta Bylina; Mathias Hoiczyk; Annemieke Cats; Paolo G Casali; Axel Le Cesne; Jürgen Treckmann; Eberhard Stoeckle; Johannes H W de Wilt; Stefan Sleijfer; Ronald Tielen; Winette van der Graaf; Cornelis Verhoef; Frits van Coevorden
Journal:  Ann Surg Oncol       Date:  2013-06-13       Impact factor: 5.344

Review 7.  Duodenal gastrointestinal stromal tumor: From clinicopathological features to surgical outcomes.

Authors:  L Marano; V Boccardi; D Marrelli; F Roviello
Journal:  Eur J Surg Oncol       Date:  2015-04-24       Impact factor: 4.424

8.  Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial.

Authors:  Ronald P Dematteo; Karla V Ballman; Cristina R Antonescu; Robert G Maki; Peter W T Pisters; George D Demetri; Martin E Blackstein; Charles D Blanke; Margaret von Mehren; Murray F Brennan; Shreyaskumar Patel; Martin D McCarter; Jonathan A Polikoff; Benjamin R Tan; Kouros Owzar
Journal:  Lancet       Date:  2009-03-18       Impact factor: 79.321

9.  Prognostic characteristics of duodenal gastrointestinal stromal tumours.

Authors:  Q Zhang; C-H Shou; J-R Yu; W-L Yang; X-S Liu; H Yu; Y Gao; Q-Y Shen; Z-C Zhao
Journal:  Br J Surg       Date:  2015-05-18       Impact factor: 6.939

  9 in total
  2 in total

1.  Impact of cirrhosis on long-term survival outcomes of patients with intrahepatic cholangiocarcinoma.

Authors:  Jian Wang; Yiwen Qiu; Yi Yang; Shu Shen; Ming Zhi; Bo Zhang; Wentao Wang
Journal:  Cancer Med       Date:  2022-04-12       Impact factor: 4.711

Review 2.  Current treatment strategies and future perspectives for gastrointestinal stromal tumors.

Authors:  Yoichi Sugiyama; Masaru Sasaki; Mohei Kouyama; Tatsuya Tazaki; Shinya Takahashi; Atsushi Nakamitsu
Journal:  World J Gastrointest Pathophysiol       Date:  2022-01-22
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.